Seal Rock Therapeutics
- Biotech or pharma, therapeutic R&D
Please note that we do not meet with service providers
As a clinical-stage biotechnology company, Seal Rock is developing a portfolio of internally discovered and developed kinase inhibitors for neurodegenerative diseases and chronic inflammatory and fibrotic liver diseases. Seal Rock’s most advanced program.
Seal Rock CEO Neil McDonnell will be giving a Company Presentation Monday, June 16 at 3:00 PM in Room 153A.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}